EIRGENIX RECEIVED "ASIA'S BEST CMO"
EirGenix was awarded "Grand Winner of Best Bioprocess Excellence in Taiwan" by Biologics Manufacturing Asia (BMA) last year; this year, EirGenix is invited to attend the ceremony in Singapore and is awarded "Asia's Best CMO".
2018 BMA conference was held in Singapore, attendees including international big pharma and biopharmaceutical companies such as Amgen, Roche, Samsung Bioepis, Novartis, Merck, and Lonza, etc. This conference brings together Asian and International Biopharmas, Biologics Contract Manufacturing Organizations, Academic and Research Institutes, and Solution Providers to convene on the best manufacturing practices in order to have access to faster, cheaper and better biologic drugs.
2018-01-31
Associated News
EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
2021/03/02
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
Vstrip® COVID-19 Antigen Rapid Test Validated and Approved in India!
2020/09/26
EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
2020/02/03
EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
2019/05/29
EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
2013/12/06
EirGenix Inc. Achieves Major Milestone: Breast Cancer Biosimilar Candidate -EG1206A Receives Favorable Response Regarding Phase III Clinical Trial Waiver
On September 24, EirGenix (6589) announced that it has received positive feedback from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during scientific consultations regarding the waiver of Phase III clinical trials for its breast cancer biosimilar candidate, EG1206A (Pertuzumab biosimilar). Consequently, the company has officially terminated the on-going Phase III clinical trial for EG1206A. This decision accelerates the global marketing authorization applications (BLA/MAA) for the product and reduces the originally planned product development expenses. Receiving positive feedback from regulatory agencies reflects EirGenix’s long-standing expertise in biosimilar development and marks a significant milestone in the company’s expansion in the biosimilar market.
2025/10/22